Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2011-006109-85-IT
EUCTR2011-006109-85-IT
Active, not recruiting
Phase 1

DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012 - RTB AIEOP 012

A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA0 sites120 target enrollmentMarch 7, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsewly diagnosed retinoblastoma patientsMedDRA version: 14.1Level: PTClassification code 10038916Term: RetinoblastomaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ewly diagnosed retinoblastoma patients
Sponsor
A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
Enrollment
120
Status
Active, not recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2012
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA

Eligibility Criteria

Inclusion Criteria

  • •Age \<18 anni • Retinoblastoma Diagnosis • None previous chemiotherapy or radiotherapy treatment • Panoramic Fundus Cam evaluation • Staging according to Classification System Intraocular Retinoblastoma e International Retinoblastoma Staging System • Performance status: Karnofsky \= 60 o Lansky \= 50\. • Informed Consent signed by the parents o a legal guardian
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 122
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\-Concomitant radiotherapy or chemotherapy or immunoomodulation \-pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomidePhase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomideMedDRA version: 9.1Level: LLTClassification code 10018336Term: GlioblastomaMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiforme
EUCTR2008-001078-34-NLMaastro Clinic57
Recruiting
Not Applicable
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with concomitant temozolomide and radiotherapy.glioblastoma10029211
NL-OMON32210Academisch Ziekenhuis Maastricht58
Recruiting
Not Applicable
Prospective observational study of newly diagnosed multiple myeloma in elderly patientsMultiple myeloma
JPRN-UMIN000010169Fukuoka Blood and Marrow Transplantation Group (FBMTG)216
Active, not recruiting
Phase 1
Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaMedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-003430-13-IEChildren's Oncology Group9,483
Completed
Not Applicable
Study on diagnosis and treatment of Mycobacterium avium complex pulmonary diseaseMycobacterium avium complex pulmonary disease
JPRN-UMIN000045542ational Hospital Organization Osaka Toneyama Medical Center94